2 - BACTERIOWEB

More documents

Recommendations

Info

28 Overexpression of acrAB and mtrCDE operons E. coli N. gonorrhoeae acrR mtrR - - acrA + + MarA acrB MtrA mtrC mtrD mtrE _ (MppA) MarR _ SoxS SoxR mutations mdr
System AcrAB-TolC in E. coli Antibiotics wild type AcrAB ++ AcrAB - Nalidixic acid 4 - 6 8.5 - 32 0.6 Norfloxacin 0.025 - 0.1 0.3 - 1.25 nd Ofloxacin 0.06 - 0.07 0.25 - 0.3 nd Ciprofloxacin 0.02 0.15 nd Ampicillin 2 - 4 5 - 6 0.6 - 2 Erythromycin 128 - 256 > 512 < 2 - 8 Tetracycline 1.25 - 3 5 - 16 0.25 - 0.3 Chloramphenicol 4 - 7.5 10 - 28 0.6 contribution to intrinsic resistance : CMI x 2-64 acquired resistance : CMI x 2-12 29 (CMI mg/l)
Page 1 and 2: Role of the Efflux Pumps in Antimic
Page 3 and 4: Cell wall Bacterial targets for ant
Page 5 and 6: Drug inactivation Target alteration
Page 7 and 8: Intracellular accumulation Drug acc
Page 9 and 10: 9 Other bacterial species with know
Page 11 and 12: Structure of bacterial efflux syste
Page 13 and 14: PMF secondary transporters Major F
Page 15 and 16: Efflux-based resistance in Staphylo
Page 17 and 18: System NorA in S. aureus Antibiotic
Page 19 and 20: Combination of mechanisms in S. aur
Page 21 and 22: PmrA-mediated resistance in S. pneu
Page 23 and 24: Other Gram positives Species System
Page 25 and 26: 25 Efflux pumps coded by mobile gen
Page 27: Efflux pumps of the RND family Bact
Page 31 and 32: Induction of acrAB-tolC expression
Page 33 and 34: RND efflux systems in P. aeruginosa
Page 35 and 36: Acquired resistance in P. aeruginos
Page 37 and 38: MexXY-mediated adaptive resistance
Page 39 and 40: Therapeutic implications of efflux
Page 41: Efflux inhibitors Phenyl-Arginyl ß

2 - BACTERIOWEB

Create successful ePaper yourself

Delete template?

Save as template?